<p>股东们可能注意到，<strong>信越化学株式会社</strong>（TSE:4063）在上周这个时候发布了第三季度业绩。早期反应并不积极，过去一周股价下跌了 8.9%，至 JP¥5,129。信越化学的收入未能达到预期，差距为 2.1%，实际收入为 JP¥6490 亿，尽管法定每股收益（EPS）为 JP¥67.51，超出预期，领先分析师预期 5.1%。对于投资者来说，这是一个重要的时刻，因为他们可以在报告中跟踪公司的表现，查看专家对明年的预测，并观察业务预期是否有变化。因此，我们收集了最新的财报后预测，以了解估计值对明年的展望。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708"/></p>
<p>TSE:4063 收益和收入增长 2026 年 1 月 30 日</p>
<p>考虑到最新的业绩，18 位分析师对信越化学的最新共识是 2027 年收入为 JP¥2.71 万亿。如果实现，这将意味着过去 12 个月收入增长 5.5%。法定每股收益预计将增长 13%，达到 JP¥292。然而，在最新业绩发布之前，分析师们曾预计 2027 年收入为 JP¥2.70 万亿，每股收益（EPS）为 JP¥293。共识分析师似乎没有在这些结果中看到任何会改变他们对业务看法的因素，因为他们的预期没有重大变化。</p>
<p>查看我们对信越化学的最新分析</p>
<p>分析师们重申了 JP¥5,582 的目标价，显示出该业务的执行情况良好，符合预期。然而，这并不是我们可以从这些数据中得出的唯一结论，因为一些投资者在评估分析师目标价时也喜欢考虑估计值的差异。对信越化学的看法存在一些差异，最乐观的分析师将其估值为 JP¥6,300，而最悲观的则为每股 JP¥4,600。正如你所看到的，分析师们对该股票的未来并不完全一致，但估计值的范围仍然相对狭窄，这可能表明结果并非完全不可预测。</p>
<p>现在从更大的视角来看，我们可以通过将这些预测与过去的表现和行业增长预期进行比较来理解它们。很明显，市场预期信越化学的收入增长将大幅放缓，预计到 2027 年底的收入年均增长率为 4.4%。相比之下，过去五年的历史增长率为 9.0%。与行业内其他公司相比，分析师们预计这些公司的收入（总体）年均增长 4.4%。因此，很明显，尽管信越化学的收入增长预计会放缓，但预计将大致与行业保持一致。</p>
<h2>结论</h2>
<p>最明显的结论是，最近业务前景没有重大变化，分析师们保持了他们的收益预测，与之前的估计一致。他们还重申了收入预期，预计公司将以与更广泛行业相似的速度增长。共识目标价保持在 JP¥5,582，最新的估计不足以对他们的目标价产生影响。</p>
<p>考虑到这一点，我们不会急于对信越化学得出结论。长期的盈利能力远比明年的利润重要。我们有来自多位信越化学分析师的估计，直到 2028 年，你可以在我们的平台上免费查看。</p>
<p>那么风险呢？每家公司都有风险，我们发现了 <strong>信越化学的 2 个警告信号</strong>，你应该知道。</p>

信越化学

SHECY

<p>信越化学报告了其第三季度业绩，营收未达到预期，低于预估 2.1%，但每股收益（EPS）超出预期 5.1%。报告发布后，股价下跌 8.9%。分析师预测 2027 年的营收为 2.71 万亿日元，反映出 5.5% 的增长，EPS 预计增长 13%，达到 292 日元。共识目标价维持在 5,582 日元，尽管与历史增长率相比，营收增长放缓，但仍显示出稳定的预期。分析师对该股票未来的看法各不相同，但总体估计表明增长与行业平均水平相符</p>

<p>Shareholders might have noticed that <strong>Shin-Etsu Chemical Co., Ltd.</strong> (TSE:4063) filed its third-quarter result this time last week. The early response was not positive, with shares down 8.9% to JP¥5,129 in the past week. Shin-Etsu Chemical missed revenue estimates by 2.1%, coming in atJP¥649b, although statutory earnings per share (EPS) of JP¥67.51 beat expectations, coming in 5.1% ahead of analyst estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p>股东们可能注意到，<strong>信越化学株式会社</strong>（TSE:4063）在上周这个时候发布了第三季度业绩。早期反应并不积极，过去一周股价下跌了 8.9%，至 JP¥5,129。信越化学的收入未能达到预期，差距为 2.1%，实际收入为 JP¥6490 亿，尽管法定每股收益（EPS）为 JP¥67.51，超出预期，领先分析师预期 5.1%。对于投资者来说，这是一个重要的时刻，因为他们可以在报告中跟踪公司的表现，查看专家对明年的预测，并观察业务预期是否有变化。因此，我们收集了最新的财报后预测，以了解估计值对明年的展望。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708" alt="" original-src="https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708"/></p>
<p>TSE:4063 Earnings and Revenue Growth January 30th 2026</p>
<div class="lb-trans"><p>TSE:4063 收益和收入增长 2026 年 1 月 30 日</p>
</div><p>Taking into account the latest results, the most recent consensus for Shin-Etsu Chemical from 18 analysts is for revenues of JP¥2.71t in 2027. If met, it would imply a satisfactory 5.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to grow 13% to JP¥292. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥2.70t and earnings per share (EPS) of JP¥293 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.</p>
<div class="lb-trans"><p>考虑到最新的业绩，18 位分析师对信越化学的最新共识是 2027 年收入为 JP¥2.71 万亿。如果实现，这将意味着过去 12 个月收入增长 5.5%。法定每股收益预计将增长 13%，达到 JP¥292。然而，在最新业绩发布之前，分析师们曾预计 2027 年收入为 JP¥2.70 万亿，每股收益（EPS）为 JP¥293。共识分析师似乎没有在这些结果中看到任何会改变他们对业务看法的因素，因为他们的预期没有重大变化。</p>
</div><p>See our latest analysis for Shin-Etsu Chemical</p>
<div class="lb-trans"><p>查看我们对信越化学的最新分析</p>
</div><p>The analysts reconfirmed their price target of JP¥5,582, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Shin-Etsu Chemical, with the most bullish analyst valuing it at JP¥6,300 and the most bearish at JP¥4,600 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>分析师们重申了 JP¥5,582 的目标价，显示出该业务的执行情况良好，符合预期。然而，这并不是我们可以从这些数据中得出的唯一结论，因为一些投资者在评估分析师目标价时也喜欢考虑估计值的差异。对信越化学的看法存在一些差异，最乐观的分析师将其估值为 JP¥6,300，而最悲观的则为每股 JP¥4,600。正如你所看到的，分析师们对该股票的未来并不完全一致，但估计值的范围仍然相对狭窄，这可能表明结果并非完全不可预测。</p>
</div><p>Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's pretty clear that there is an expectation that Shin-Etsu Chemical's revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 4.4% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 4.4% annually. So it's pretty clear that, while Shin-Etsu Chemical's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.</p>
<div class="lb-trans"><p>现在从更大的视角来看，我们可以通过将这些预测与过去的表现和行业增长预期进行比较来理解它们。很明显，市场预期信越化学的收入增长将大幅放缓，预计到 2027 年底的收入年均增长率为 4.4%。相比之下，过去五年的历史增长率为 9.0%。与行业内其他公司相比，分析师们预计这些公司的收入（总体）年均增长 4.4%。因此，很明显，尽管信越化学的收入增长预计会放缓，但预计将大致与行业保持一致。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at JP¥5,582, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>最明显的结论是，最近业务前景没有重大变化，分析师们保持了他们的收益预测，与之前的估计一致。他们还重申了收入预期，预计公司将以与更广泛行业相似的速度增长。共识目标价保持在 JP¥5,582，最新的估计不足以对他们的目标价产生影响。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on Shin-Etsu Chemical. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Shin-Etsu Chemical analysts - going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>考虑到这一点，我们不会急于对信越化学得出结论。长期的盈利能力远比明年的利润重要。我们有来自多位信越化学分析师的估计，直到 2028 年，你可以在我们的平台上免费查看。</p>
</div><p>And what about risks? Every company has them, and we've spotted <strong>2 warning signs for Shin-Etsu Chemical</strong> you should know about.</p>
<div class="lb-trans"><p>那么风险呢？每家公司都有风险，我们发现了 <strong>信越化学的 2 个警告信号</strong>，你应该知道。</p>
</div>

信越化学公司业绩超出分析师预期：看看市场共识对明年的预测